IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human ...( - Company continues to anticipate...),Health

- Company continues to anticipate CHMP opinion in the third quarter; L-MTP-PE on track for final European Commission decision in the fourth

quarter

IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133). The Company expects to complete the additional data analyses, respond to questions received from the CHMP regarding the recent inspection of the Children's Oncology Group (COG), and address the remaining chemistry, manufacturing and control (CMC) issues by the end of August according to the current CHMP timeline. It is anticipated that the CHMP will consider the Company's responses at its meeting in September 2008, when an oral explanation hearing will be held if required. The Company continues to expect resolution of the remaining issues regarding the Marketing Authorization Application (MAA) for L-MTP-PE in the third quarter.

"The European review of L-MTP-PE continues to progress as expected as we work with the CHMP to address the additional data analyses as well as the remaining questions," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We remain optimistic that we will have the CHMP opinion on L-MTP-PE in the third quarter this year."

With the CHMP opinion anticipated in the third quarter, IDM Pharma expects a decision from the European Commission in the fourth quarter of 2008. If approved for Marketing Authorization by the European Commission, L-MTP-PE will be the first treatment in more than 20 years approved for patients with osteosarcoma, a rare and often fatal bone tumor
'/>"/>